#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
Gayatri Devi, a neurologist specializing in memory disorders, explains that dementia is best understood as a spectrum of overlapping pathologies—Alzheimer's, vascular, Lewy body, and mixed—rather than a single disease. She discusses the role of neuroinflammation and viral infections in Alzheimer's progression and her approach to detecting subtle cognitive decline in high-functioning patients. The conversation covers the benefits and risks of anti-amyloid therapies like lecanemab and donanemab, including monitoring for ARIA. Dr. Devi also introduces her concept of menopause-related cognitive impairment, a reversible condition often mistaken for early dementia, and examines why women face a higher Alzheimer's risk. The episode highlights the shift toward personalized, multimodal dementia care and the promise of early detection and AI-assisted monitoring.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Canon
•
Dementia as a Spectrum Disease00:07:15
Dr. Devi explains that dementia encompasses multiple overlapping pathologies—including Alzheimer's, vascular, Lewy body, and mixed presentations—and that a spectrum view is essential for accurate diagnosis and treatment.
Dr. Devi highlights the emerging evidence that neuroinflammation, driven in part by viral infections, plays a significant role in Alzheimer's disease progression.
Dr. Devi introduces her concept of menopause-related cognitive impairment—a distinct clinical entity where perimenopausal hormonal shifts cause significant cognitive fog that can be mistaken for early dementia.
Why Forgetting Names Is Usually Normal and When It Becomes Concerning00:29:00
Dr. Devi distinguishes between common age-related forgetfulness—such as struggling to retrieve names—and pathological word-finding problems that may signal cognitive decline.
Anti-Amyloid Therapies: Benefits, Risks, and Patient Selection
Dr. Devi discusses lecanemab, donanemab, and other anti-amyloid monoclonal antibodies, emphasizing the importance of careful patient selection and monitoring for complications like ARIA (amyloid-related imaging abnormalities).
Dr. Devi explains the multifactorial reasons women face a greater lifetime risk of Alzheimer's disease, including hormonal changes, genetic factors like APOE4, and longer life expectancy.